Tumor Resident, B-Cell Receptor Chemical Characteristics Associated with Better Overall Survival for Neuroblastoma

Kacsoh, Dorottya B.; Patel, Dhruvil; Hsiang, Monica; Gozlan, Etienne C.; Chobrutskiy, Andrea; Chobrutskiy, Boris I.; Blanck, George

doi:10.1007/s12031-022-02050-6

Cited by 1 publication

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there have been many studies on the prognosis of NB, most of them only involved an individual prognostic factor or focused on investigating the prognostic factors influencing the OS of NB patients rather than the CCS and EFS of NB. [17][18][19][20] Most children with NB were already in the INSS stage 4 and COG high-risk group at the time of diagnosis, so their prognosis was generally poor, and they were prone to tumor recurrence or metastasis or even death after systematic treatment with surgery combined with chemotherapy. [21] The recurrence and metastasis of tumors, even if they did not cause immediate death, could bring considerable trauma and burden to the physical and mental health of the children and their families.…”

Section: Discussionmentioning

confidence: 99%

A novel clinical tool and risk stratification system for predicting the event-free survival of neuroblastoma patients: A TARGET-based study

Li,

Duan,

et al. 2023

Medicine

View full text Add to dashboard Cite

Neuroblastoma (NB), considered the most common non-intracranial solid tumor in children, accounts for nearly 8% of pediatric malignancies. This study aimed to develop a simple and practical nomogram to predict event-free survival (EFS) in NB patients and establish a new risk stratification system. In this study, 763 patients primarily diagnosed with NB in the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) database were included and randomly assigned to a training set (70%) and a validation set (30%) in a 7:3 ratio. First, the independent prognostic factors of EFS for NB patients were identified through univariate and multivariate Cox regression analyses. Second, a nomogram was created based on these factors and was validated for calibration capability, discriminative, and clinical significance by C-curves, receiver operating characteristic (ROC) curves, and decision curve analysis. Finally, a new risk stratification system was established for NB patients based on the nomogram. The univariate Cox analysis demonstrated that NB patients with age at diagnosis >318 days, International Neuroblastoma Staging System (INSS) stage 4, DNA diploidy, MYCN amplification status, and children oncology group (COG) high-risk group had a relatively poor prognosis. However, according to the multivariate Cox regression analysis, only age, INSS stage, and DNA ploidy were independent predictive factors in NB patients regarding EFS, and a nomogram was created based on these factors. The area under the curve (AUC) values of the ROC curves for the 3-, 5-, and 10-year EFS of this nomogram were 0.681, 0.706, and 0.720, respectively. Additionally, the AUC values of individual independent prognostic factors of EFS were lower than those of the nomogram, suggesting that the developed nomogram had a higher predictive reliability for prognosis. In addition, a new risk stratification system was developed to better stratify NB patients and provide clinical practitioners with a better reference for clinical decision-making. NB patients’ EFS could be predicted more accurately and easily through the constructed nomogram and event-occurrence risk stratification system, allowing clinicians to better differentiate NB patients and establish individualized treatment plans to maximize patient benefits.

show abstract